0000950170-24-084346.txt : 20240717 0000950170-24-084346.hdr.sgml : 20240717 20240717173534 ACCESSION NUMBER: 0000950170-24-084346 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240715 FILED AS OF DATE: 20240717 DATE AS OF CHANGE: 20240717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knight Jeff E. CENTRAL INDEX KEY: 0001881007 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 241123128 MAIL ADDRESS: STREET 1: CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-07-15 false 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001881007 Knight Jeff E. C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 false true false false Chief Operating Officer true Common Stock 2024-07-15 4 M false 17499 23.98 A 70079 D Common Stock 2024-07-15 4 M false 2887 20.02 A 72966 D Common Stock 2024-07-15 4 M false 5687 19.64 A 78653 D Common Stock 2024-07-15 4 S false 27000 55.00 D 51653 D Stock option (Right to Buy) 23.98 2024-07-15 4 M false 17499 0 D 2031-09-01 Common Stock 17499 112501 D Stock option (Right to Buy) 20.02 2024-07-15 4 M false 2887 0 D 2032-02-29 Common Stock 2887 20213 D Stock option (Right to Buy) 19.64 2024-07-15 4 M false 5687 0 D 2033-03-01 Common Stock 5687 85313 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. 1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Marc Wilson, as attorney-in-fact 2024-07-17